Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 GlobeNewswire - Sun Apr 19, 6:00PM CDT

WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

MNPR : 65.52 (+3.06%)
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update GlobeNewswire - Fri Mar 27, 12:00PM CDT

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative...

MNPR : 65.52 (+3.06%)
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer GlobeNewswire - Mon Mar 2, 7:00AM CST

WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative treatments...

MNPR : 65.52 (+3.06%)
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments GlobeNewswire - Thu Nov 13, 2025

WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments...

MNPR : 65.52 (+3.06%)
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025 GlobeNewswire - Sun Nov 9, 2025

WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

MNPR : 65.52 (+3.06%)
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 GlobeNewswire - Wed Oct 15, 2025

WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments...

MNPR : 65.52 (+3.06%)
Raymond James Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR) Tipranks - Tue Oct 7, 2025

In a report released today, Christopher Raymond from Raymond James maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $142.00. The company’s shares closed last Friday at $99.39.Elevate...

MNPR : 65.52 (+3.06%)
Oppenheimer Sticks to Their Buy Rating for Monopar Therapeutics Inc (MNPR) Tipranks - Fri Oct 3, 2025

Oppenheimer analyst Andreas Argyrides maintained a Buy rating on Monopar Therapeutics Inc today and set a price target of $115.00. The company’s shares closed yesterday at $84.73.Elevate Your Investing...

MNPR : 65.52 (+3.06%)
Analysts’ Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN) Tipranks - Fri Oct 3, 2025

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), Repligen (RGEN – Research Report) and Monopar Therapeutics...

MNPR : 65.52 (+3.06%)
RGEN : 115.91 (-6.12%)
MAZE : 25.75 (+0.90%)

Barchart Exclusives

Quantum Stocks Have Been Mostly Hype. IonQ May Be the Real Deal. Barchart - 40 seconds ago
Quantum stocks have been promising the future for years, but IonQ, with its astounding revenue growth, is now delivering. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.